<DOC>
	<DOCNO>NCT02435329</DOCNO>
	<brief_summary>This study part research project University MD Program . This observational study aim compare difference bone metabolism microcirculation patient type 2 diabetes mellitus ( without diabetic neuropathy Charcot foot ) healthy subject . Diabetes gradually become global epidemic along associated complication . Diabetes affect several system body particularly eye , nerve kidney . The damaging effect occur level small blood vessel ( microcirculation ) supply vital structure . Normally , inner line blood vessel ( endothelium ) play important role maintain adequate blood flow . The endothelium release chemical substance call nitric oxide , relax small blood vessel thereby ensure sufficient blood supply key structure . Nitric oxide also prevent blockage vessel . Any form metabolic stress like hyperglycaemia ( raise blood sugar see diabetes ) cause abnormal change normal behaviour endothelium ( endothelial dysfunction ) . Therefore hyperglycaemia promote endothelial dysfunction lower nitric oxide level , may lead diabetic complication like diabetic retinopathy ( eye damage ) , nephropathy ( kidney damage ) neuropathy ( nerve damage ) . In addition , patient diabetes also suffer osteoporosis ( thin bone ) . Osteoporosis bone disorder characterise reduction bone mineral content lead increase risk develop fracture . The increase risk fracture patient type 2 diabetes attribute poor bone quality result harmful effect high blood glucose . Studies also show nitric oxide bone protective effect demonstrate ability prevent bone fragmentation improve bone strength . Study marker endothelial function bone metabolism facilitate well understand origin diabetic complication . This aid development novel therapeutic agent target harmful trigger diabetes eventually may prevent retard onset debilitate diabetic complication .</brief_summary>
	<brief_title>Microcirculation Bone Metabolism Patients With Type 2 Diabetes Mellitus Charcot Foot - A Pilot Study</brief_title>
	<detailed_description>This observational study aim observe compare difference bone metabolism microcirculation patient type 2 diabetes healthy control . In study , 50 participant recruit categorise follow group : 1 . Control group : 10 healthy volunteer ( Hospital staff spouses/ partner patient volunteer healthy subject ) 2 . Type 2 diabetic patient without neuropathy : 10 3 . Type 2 diabetic patient neuropathy : - 10 patient painless neuropathy - 10 patient painful neuropathy 4 . Type 2 diabetic patient unilateral Charcot foot : 10 Visit Schedule The estimated time enrollment patient within 3 month . The duration study 5 month . Screening ( -2 Weeks ) : To assess eligibility . This include informed consent process , medical history physical examination , screen neuropathy routine blood . Laboratory work-up do screening consider data analysis . Visit 1 - Baseline visit - Anthropometric measure : Height , weight , BMI , waist circumference - Vital parameter : supine stand blood pressure , pulse , respiratory rate temperature - Laboratory assessment include marker endothelial activation , inflammation bone metabolism . - Markers endothelial activation investigate use systemic protein suspension array technology . For e.g . adhesion molecule like ICAM , VCAM inflammatory molecule . - Nitric oxide analyse use Griess assay - Bone turnover marker [ e.g. , P1NP ( Procollagen type 1 amino terminal propeptide ) , CTX ( C-terminal cross-linked telopeptide type-I collagen ) , Sclerostin , RANKL ( receptor activator nuclear factor ( NF ) -kB ( RANK ) ligand ) , OPG ( osteoprotegerin ) , OPN ( osteopontin ) , OCN ( osteocalcin ) , BMP4 ( Bone morphogenetic protein 4 ) TGF-1β ( Transforming growth factor-1β ) - use ELISA ( enzyme-linked immunosorbent assay ) . - IL-6 - Interleukin-6 , inflammatory cytokine implicate osteoporosis ( use ELISA ) - Assessment skin microcirculation Laser Doppler Iontophoresis - Assessment calcaneal bone mineral density ( BMD ) Bone Sonometer ( ultrasound ) - Advanced glycation end-products assessed AGE reader use technique skin autofluorescence Clinical Procedures Assessment microcirculation Laser Doppler Iontophoresis : A standard measurement microcirculation laser Doppler iontophoresis , use several research institute . In trial skin microcirculation measure dorsum foot use Perimed Laser Doppler imager iontophoresis system . Endothelial-mediated vasodilation measure iontophoresis acetylcholine , sodium nitroprusside used measure endothelium-independent vasodilation . The iontophoresis system consist ION chamber ( iontophoresis delivery vehicle device ) stick firmly skin reference electrode . The response blood flow image quantified use Perimed Laser Doppler Imager ( PeriScan PIMII ; Perimed , Sweden ) . Analysis AGE : An AGE reader , utilizes principle skin autofluorescence , measure accumulation AGE skin . This validated device provide real-time , non-invasive assessment cardiovascular risk chronic disease like Diabetes , renal failure , cardiovascular disease , etc . AGE-modified protein autofluorescent property excite ultraviolet ( UV ) light emit fluorescence particular wavelength . The level AGE skin correlate AGE level blood . The volar aspect forearm place AGE reader , equip UV light source . The UV light trigger AGE skin , penetrate 1mm dermis , emit autofluorescence detect AGE reader . The intensity fluorescence correlate quantity AGE skin . Assessment calcaneal BMD : This simple convenient method assess peripheral BMD ass fracture risk . The device use quantitative ultrasound call Sahara Clinical Bone Sonometer ( Sahara Clinical Bone Sonometer ; Hologic , Waltham , MA ) . The calcaneus preferred peripheral site assess fracture risk . This device use ultrasound wave determine BMD calcaneus . In procedure , bare heel place device , BMD calculate within 30 second result generate paper device .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Diabetic Angiopathies</mesh_term>
	<criteria>• Subjects age 4075 year Healthy subject nondiabetic subject control group . A diagnosis type 2 DM base one follow criterion ( ADA 2010 ) : Fasting plasma glucose ( FPG ) ≥ 126 mg/dL ( 7.0 mmol/L ) 2h plasma glucose ≥ 200 mg/dl ( 11.1 mmol/L ) OGTT Classic symptoms hyperglycaemia hyperglycaemic crisis random plasma glucose ≥ 200 mg/dL ( 11.1 mmol/L ) . Patients treatment type 2 diabetes mellitus Presence diabetic neuropathy confirm 2 follow neurological test positive examination ( vibration perception threshold , 10 gm . monofilament , 128 Hz tune fork , ankle reflex , pinprick ) Painful diabetic neuropathy diagnose accord LANSS ( Leeds Assessment Neuropathic Symptoms Signs ) score For patient chronic Charcot foot , diagnosis confirm clinical judgment radiologic examination Xray , technetiumlabeled bisphosphonate bone scan MRI ) • At screening , age 40 year 75 year . Type 1 diabetes mellitus ( patient history ketoacidosis , age onset DM 25 year age , BMI &lt; 21 kg/m2 use insulin without concomitant oral hypoglycemic agent ) Major cardiovascular complication within 3 month prior screen Recent history smoking within last 6 month Scars , tattoo rash forearm Recent current oral steroid therapy topical steroid apply forearm Patients uncontrolled hypertension ( systolic blood pressure [ SBP ] &gt; 160/90 mmHg ) hypotension ( SBP ≤ 100 mm Hg diastolic BP ≤60 mm Hg ) screening . History general systemic illness include cardiac , hepatic renal insufficiency Patients renal insufficiency characterize creatinine clearance le 60 ml/min serum creatinine 130 μmol/l Receiving treatment inflammatory disease malignancy Other nondiabetic cause neuropathy History chronic alcohol consumption History metabolic bone disorder ( Osteoporosis , Paget 's disease , etc . ) treatment bone disorder ( past current treatment osteoporosis , bisphosphonate therapy within last 3 year ) History malignancy History active foot ulcer History concomitant therapy may interfere bone metabolism e.g . glucocorticoid ( within last 3 month ) , hormone replacement therapy ( last 12 month ) , SERM ( selective oestrogen receptor modulator ) , thiazolidinedione , anticonvulsant use Receiving drug fluoresce ( e.g. , Doxorubicin , Daunomycin , Camptothecin , Protoporphyrin , Fluoroquinolones , Tetracycline , Hydroxychloroquine Quinidine ) History photosensitivity reaction ( e.g. , sensitive ultraviolet light , take medication know cause photosensitivity Simultaneous participation clinical trial involvement another research trial involve investigational product past 12 week .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>